Viltolarsen (Iftikhar et al. 2021) is an antisense oligonucleotide approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a specific DMD gene mutation. This evidence concerns the gene DMD and Duchenne muscular dystrophy.